Century Therapeutics Selected for Oral Presentations of CNTY-813 Preclinical Data at EASD 2026 and Breakthrough T1D® Clinical & Research Congress 2026

Century Therapeutics (NASDAQ: IPSC) aims to file for FDA approval of its diabetes cell therapy, CNTY-813, in Q4 2026, with initial human data expected in 2027. The company reported $197.2M in cash as of Q2 2026, sufficient to fund operations into Q1 2029. Preclinical results showed promising glucose control and immune evasion, but clinical outcomes are not guaranteed. Century also advances CNTY-308, a CAR-iT cell therapy, with IND-enabling work on track for 2026. Q2 R&D expenses decreased 27% to

Century Therapeutics, Inc. (IPSC) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Century Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates · Completed pre-IND meeting with the FDA for CNTY-813, an iPSC-derived islet replacement therapy with functional cure potential in type 1 diabetes (T1D); IND submission on track f

BioPharma Dive roundup covers AstraZeneca’s eplontersen failure in a major heart disease study, boosting expectations for rival TTR amyloidosis drugs from Alnylam and BridgeBio. Other items include ARPA-H funding, GSK ending a neuroscience alliance with Alector, Vera Therapeutics’ FDA nod for IgA nephropathy, and Vertex’s $10B plan to buy Crinetics.

Century Therapeutics (NASDAQ: IPSC) presented new preclinical results for CNTY-813, an iPSC-derived islet replacement engineered with Allo-Evasion™ 5.0, at ADA 2026. The company said transplanted cells maintained normoglycemia for over eight months in mice, with glucose normalization within 60 minutes in glucose tolerance tests. It also reported >50% beta-cell composition, no tumorigenesis in >140 mice, and immune evasion in humanized models without immunosuppression. Century said Phase 1 manufa

Micron Technology plans a $10 billion investment in U.S. research labs for AI and advanced computing, according to a company release. President Trump praised the move, attributing it to his administration's policies. The investment aims to create jobs and bolster U.S. leadership in critical technologies, with a focus on memory and semiconductor research.

Moderna (MRNA) and Merck (MRK) announced positive Phase 3 trial results for their personalized mRNA cancer vaccine combined with Keytruda, meeting primary goals. Moderna's shares surged 177%, adding $44 billion to its market value, while Merck's shares rose 12%. The trial showed extended time without melanoma recurrence and reduced risk of cancer spread. Moderna CEO called it a validation of a new class of medicine, with analysts expecting regulatory approval soon.